KOICHI TAKAHASHI to Daunorubicin
This is a "connection" page, showing publications KOICHI TAKAHASHI has written about Daunorubicin.
Connection Strength
0.204
-
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
Score: 0.164
-
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
Score: 0.040